Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Clinics ; 71(8): 435-439, Aug. 2016. tab
Artículo en Inglés | LILACS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: lil-794635

RESUMEN

OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness of LDE-paclitaxel on inpatients with aortic atherosclerosis. METHODS: This study tested a 175 mg/m2 body surface area dose of LDE-paclitaxel (intravenous administration, 3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed. RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at 1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the LDE-paclitaxel group and one death occurred in the control group. CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed the potential to reduce atherosclerotic lesion size.


Asunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Enfermedades de la Aorta/tratamiento farmacológico , Colesterol/uso terapéutico , Paclitaxel/uso terapéutico , Aterosclerosis/tratamiento farmacológico , Moduladores de Tubulina/uso terapéutico , Nanopartículas/uso terapéutico , Aorta Torácica/efectos de los fármacos , Enfermedades de la Aorta/diagnóstico por imagen , Factores de Tiempo , Triglicéridos/sangre , Angiografía , Colesterol/sangre , Reproducibilidad de los Resultados , Resultado del Tratamiento , Sistemas de Liberación de Medicamentos , Aterosclerosis/diagnóstico por imagen , Emulsiones Grasas Intravenosas/uso terapéutico , Tomografía Computarizada Multidetector
2.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 10(5): 553-570, Setembro/Outubro 2000. tab
Artículo en Portugués | LILACS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1066775

RESUMEN

No contexto desta revisão sobre hipertensão pulmonar o presente artigo aborda o papel dos diferentes exames utilizados para avaliação anatômica e funcional da circulação pulmonar, com realce para os baseados em imageamento com diversos métodos.


Asunto(s)
Angiografía/métodos , Angiografía/tendencias , Ecocardiografía/métodos , Ecocardiografía/tendencias , Espectroscopía de Resonancia Magnética/métodos , Hipertensión Pulmonar/diagnóstico , Radiología/métodos , Tomografía Computarizada de Emisión/métodos , Tomografía Computarizada de Emisión/tendencias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA